TTR and hypertrophic cardiomyopathy: The control cohort included 48 patients with wild‐type or mutated transthyretin amyloidosis (n = 34), AA amyloidosis (n = 1), or hypertrophic cardiomyopathy unrelated to an amyloidosis process (n = 13).